
Lifyorli Shows Survival Benefit Across Ovarian Cancer Subgroups
Corcept Highlights New ROSELLA Data at ASCO 2026 Demonstrating Broad Survival Benefits of Lifyorli in Platinum-Resistant Ovarian Cancer Corcept Therapeutics has unveiled new findings from its pivotal Phase 3 ROSELLA clinical trial at the 2026 American Society of Clinical Oncology…












